Developer docs
API playgroundTry for free, no card

Search company profiles

Maverex

Full company profile

uuid000safa

Namestring
Maverex
Legal namestring
Maverex Limited
Websiteurl
maverex.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Maverex Limited is a privately-held health economics and outcomes research (HEOR) and market access consultancy headquartered in Newcastle upon Tyne, United Kingdom, with a registered office in London. Founded in 2016, the firm employs over 35 specialists with backgrounds spanning health economics, market access, statistics, and epidemiology, and serves global pharmaceutical and medical technology companies. Its operating model is professional services: project-based, quote-priced consulting engagements delivered by cross-functional teams, with most business conducted on a repeat basis through multi-year contracts.

The firm's service portfolio comprises seven integrated practices: Global Market Access Strategy, Real World Evidence, Environmental Sustainability Assessments, Health Economic Modelling, HTA Support, Value Communications, and Evidence Synthesis (including literature reviews, meta-analyses, and statistical support). Underlying technology is grounded in established HEOR and Health Technology Assessment methodologies — cost-effectiveness analysis, cost-consequence analysis, budget impact modelling, and systematic evidence synthesis — rather than proprietary software platforms. The differentiating technical capability is an industry-leading environmental sustainability assessment methodology that quantifies emissions and resource use driven by treatment choices and patient pathways, positioning Maverex at the intersection of HEOR and ESG advisory. The firm supports engagements across the product lifecycle, from pre-clinical Phase I through lifecycle management.

Maverex generates revenue through custom, project-based fees billed against multi-year contracts with enterprise clients. Its go-to-market is enterprise field sales targeting Top 5 and Top 20 global biopharma, Fortune 500 pharmaceutical and medical device companies, and select startup biopharma. Delivery is structured to support clients across EMEA, Americas, and APAC. Maverex Limited is founder-owned, with no disclosed funding rounds, no parent company, no acquisitions, and no subsidiaries. The firm holds Women Owned certification and has obtained Science Based Targets initiative (SBTi) approval of its near-term science-based emissions reduction target, aligning its own ESG posture with the advisory area in which it is positioning as a market leader.

Short descriptiontext

Maverex is a UK-based HEOR and market access consultancy employing 35+ specialists to deliver health economic modelling, HTA support, real-world evidence, value communications, and environmental sustainability assessments to global pharmaceutical and medical technology companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNewcastle Upon Tyne, United Kingdom
HQ citystring
Newcastle Upon Tyne
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
market access consulting, health economics research, HTA submissions, evidence synthesis, environmental sustainability assessment
Industry3 codes
PRIMARYHLAIAKAB
Health Economics & Outcomes Research (HEOR)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
SECONDARYHLAIAKAD
Payer & HTA Engagement (Reimbursement/Submissions)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
SECONDARYBPAHAJAH
Sustainability, ESG & Climate Risk Advisory
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Healthcare Market Access Consulting
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Consulting Services
TypeProfessional Services
Description

Professional consulting services provided to global Pharma and MedTech companies for market access strategy, HTA support, real world evidence, value communications, and environmental sustainability assessments. Revenue generated through project-based consulting engagements.

maverex.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing is quote-based and tailored to individual client requirements. No public pricing information available.

maverex.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Maverex is a HEOR and market access consultancy that provides strategic consulting services to global pharmaceutical, medical device, and diagnostic companies. Its core offering is an integrated suite of services spanning the product lifecycle — including global market access strategy, real world evidence, environmental sustainability assessments, health economic modelling, HTA submission support, value communications, and evidence synthesis. The firm is recognised as an industry leader in environmental sustainability assessments for healthcare products and care pathways.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Distribution of take-home naloxone decreased overdose deaths by around 6.6% and was cost-effective with incremental cost per QALY gained of £899
+1 more record
Product overview1 text field

Maverex is a HEOR and market access consultancy that offers a unified suite of services rather than a traditional software product platform. Their core offerings include Global Market Access Strategy, Real World Evidence, Environmental Sustainability Assessments, Economic Modelling, HTA Support, Value Communications, and Evidence Synthesis. These services work together as an integrated consultancy offering, with specialized cross-functional teams providing strategic insight grounded in extensive experience to help global Pharma and MedTech companies achieve market access and deliver innovation to patients worldwide. The company is particularly noted as an industry leader in environmental sustainability assessments for healthcare products and care pathways.

Product and service7 records
1Global Market Access Strategy
CategoryMarket Access Consulting
Description

Strategic market access consulting to help pharmaceutical and MedTech companies achieve optimal reimbursement and formulary positioning across global markets, spanning pre-clinical, pivotal, pre-launch, early commercialisation, and lifecycle management phases.

2Real World Evidence
CategoryReal World Evidence / HEOR
Description

Collection and analysis of real-world data to support market access, health economics, and regulatory decisions for pharmaceutical and MedTech clients.

3Environmental Sustainability Assessments
CategoryEnvironmental Sustainability Consulting
Description

Industry-leading assessments of environmental emissions and resource use driven by treatment choices and patient pathways, helping payers and policymakers meet sustainability goals.

4Economic Modelling
CategoryHealth Economic Modelling / HEOR
Description

Health economic modelling services including cost-effectiveness analysis, cost-consequence analysis, and budget impact models across therapeutic areas such as oncology, cardiovascular, respiratory, and autoimmune diseases, built for HTA submissions.

5HTA Support
CategoryHTA Consulting
Description

Health Technology Assessment submission support including evidence synthesis, dossier preparation, and engagement with HTA bodies for pharmaceutical and MedTech clients.

6Value Communications
CategoryValue Communications Consulting
Description

Development and articulation of value propositions and evidence packages for regulators, HTA bodies, payers, and other stakeholders.

7Evidence Synthesis
CategoryEvidence Synthesis / HEOR
Description

Literature reviews, meta-analyses, and statistical support services to synthesise clinical and economic evidence for market access and HTA purposes.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Maverex has an SBTi-approved near-term science-based emissions reduction target. This partnership demonstrates Maverex's commitment to environmental sustainability and positions them as leaders in integrating environmental evidence in market access and policy strategy.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Smaller HEOR and market access consultancy serving pharma clients with evidence synthesis and HTA support — comparable niche positioning at an earlier scale stage.

TypeDirect peer
Description

UK-based health economics and market access consultancy offering similar HEOR, HTA, and value communication services to pharma and MedTech clients. Most direct comparable by size, geography, and service mix.

TypeDirect peer
Description

UK-headquartered market access and HEOR consultancy serving pharma and medical device companies with pricing, reimbursement, and HTA submission support — directly comparable niche competitor.

TypeDirect peer
Description

Global medical communications and HEOR/market access consultancy serving pharma clients across the product lifecycle. Comparable service portfolio with broader scale.

TypeDirect peer
Description

Specialist market access and HEOR consultancy providing evidence synthesis, value communications, and HTA support to pharma and biotech — a similar niche player in the same service categories.

TypeDirect peer
Description

Specialized HEOR, market access, and real-world evidence consultancy within RTI International, serving pharma and MedTech with comparable deliverables (economic modelling, evidence synthesis, HTA support).

TypeBroad incumbent
Description

Large HEOR and market access consultancy (part of Thermo Fisher's PPD) offering the full suite of services Maverex provides plus broader real-world evidence, epidemiology, and clinical outcomes — a much larger, established competitor.

TypeBroad incumbent
Description

Global leader in life sciences data, technology, and consulting, with a substantial HEOR and market access practice. Provides overlapping capabilities at significantly greater scale and geographic reach than Maverex.

TypeBroad incumbent
Description

Global consulting firm with a life sciences practice offering HEOR, pricing, and market access strategy. Overlaps with Maverex's strategic consulting offering but as part of a broader portfolio.

TypeOthers
Description

Provides market access data, analytics, and HEOR research to pharma clients — thematically adjacent as both serve the same buyer function for evidence-based market access decisions.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Maverex

Healthcare Market Access Consultingmaverex.com

Maverex is a UK-based HEOR and market access consultancy employing 35+ specialists to deliver health economic modelling, HTA support, real-world evidence, value communications, and environmental sustainability assessments to global pharmaceutical and medical technology companies.

What Maverex does

Maverex Limited is a privately-held health economics and outcomes research (HEOR) and market access consultancy headquartered in Newcastle upon Tyne, United Kingdom, with a registered office in London. Founded in 2016, the firm employs over 35 specialists with backgrounds spanning health economics, market access, statistics, and epidemiology, and serves global pharmaceutical and medical technology companies. Its operating model is professional services: project-based, quote-priced consulting engagements delivered by cross-functional teams, with most business conducted on a repeat basis through multi-year contracts.

The firm's service portfolio comprises seven integrated practices: Global Market Access Strategy, Real World Evidence, Environmental Sustainability Assessments, Health Economic Modelling, HTA Support, Value Communications, and Evidence Synthesis (including literature reviews, meta-analyses, and statistical support). Underlying technology is grounded in established HEOR and Health Technology Assessment methodologies — cost-effectiveness analysis, cost-consequence analysis, budget impact modelling, and systematic evidence synthesis — rather than proprietary software platforms. The differentiating technical capability is an industry-leading environmental sustainability assessment methodology that quantifies emissions and resource use driven by treatment choices and patient pathways, positioning Maverex at the intersection of HEOR and ESG advisory. The firm supports engagements across the product lifecycle, from pre-clinical Phase I through lifecycle management.

Maverex generates revenue through custom, project-based fees billed against multi-year contracts with enterprise clients. Its go-to-market is enterprise field sales targeting Top 5 and Top 20 global biopharma, Fortune 500 pharmaceutical and medical device companies, and select startup biopharma. Delivery is structured to support clients across EMEA, Americas, and APAC. Maverex Limited is founder-owned, with no disclosed funding rounds, no parent company, no acquisitions, and no subsidiaries. The firm holds Women Owned certification and has obtained Science Based Targets initiative (SBTi) approval of its near-term science-based emissions reduction target, aligning its own ESG posture with the advisory area in which it is positioning as a market leader.

Maverex firmographics

Firmographics
Name
Maverex
Legal name
Maverex Limited
Website
https://maverex.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Maverex is a UK-based HEOR and market access consultancy employing 35+ specialists to deliver health economic modelling, HTA support, real-world evidence, value communications, and environmental sustainability assessments to global pharmaceutical and medical technology companies.
Ownership category
akta.pro rank

Maverex industry classification

Industry
Product category
Healthcare Market Access Consulting
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAKAB
Health Economics & Outcomes Research (HEOR)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
SECONDARYHLAIAKAD
Payer & HTA Engagement (Reimbursement/Submissions)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
SECONDARYBPAHAJAH
Sustainability, ESG & Climate Risk Advisory

Keywords

  • Market access consulting
  • Health economics research
  • HTA submissions
  • Evidence synthesis
  • Environmental sustainability assessment

Where Maverex is headquartered

Location

Headquarters

HQ city
Newcastle Upon Tyne
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Maverex business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Consulting Services: Professional consulting services provided to global Pharma and MedTech companies for market access strategy, HTA support, real world evidence, value communications, and environmental sustainability assessments. Revenue generated through project-based consulting engagements.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Maverex product offering

Product offering

Core offering

Maverex is a HEOR and market access consultancy that provides strategic consulting services to global pharmaceutical, medical device, and diagnostic companies. Its core offering is an integrated suite of services spanning the product lifecycle — including global market access strategy, real world evidence, environmental sustainability assessments, health economic modelling, HTA submission support, value communications, and evidence synthesis. The firm is recognised as an industry leader in environmental sustainability assessments for healthcare products and care pathways.

Product overview

Maverex is a HEOR and market access consultancy that offers a unified suite of services rather than a traditional software product platform. Their core offerings include Global Market Access Strategy, Real World Evidence, Environmental Sustainability Assessments, Economic Modelling, HTA Support, Value Communications, and Evidence Synthesis. These services work together as an integrated consultancy offering, with specialized cross-functional teams providing strategic insight grounded in extensive experience to help global Pharma and MedTech companies achieve market access and deliver innovation to patients worldwide. The company is particularly noted as an industry leader in environmental sustainability assessments for healthcare products and care pathways.

Differentiator

Problem solved

Functional benefit

Products and services

  • Global Market Access Strategy Strategic market access consulting to help pharmaceutical and MedTech companies achieve optimal reimbursement and formulary positioning across global markets, spanning pre-clinical, pivotal, pre-launch, early commercialisation, and lifecycle management phases.
  • Real World Evidence Collection and analysis of real-world data to support market access, health economics, and regulatory decisions for pharmaceutical and MedTech clients.
  • Environmental Sustainability Assessments Industry-leading assessments of environmental emissions and resource use driven by treatment choices and patient pathways, helping payers and policymakers meet sustainability goals.
  • Economic Modelling Health economic modelling services including cost-effectiveness analysis, cost-consequence analysis, and budget impact models across therapeutic areas such as oncology, cardiovascular, respiratory, and autoimmune diseases, built for HTA submissions.
  • HTA Support Health Technology Assessment submission support including evidence synthesis, dossier preparation, and engagement with HTA bodies for pharmaceutical and MedTech clients.
  • Value Communications Development and articulation of value propositions and evidence packages for regulators, HTA bodies, payers, and other stakeholders.
  • Evidence Synthesis Literature reviews, meta-analyses, and statistical support services to synthesise clinical and economic evidence for market access and HTA purposes.

Quantifiable outcome

  • Distribution of take-home naloxone decreased overdose deaths by around 6.6% and was cost-effective with incremental cost per QALY gained of £899
  • +1 more outcomes

Companies that use Maverex

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles3 records

Maverex technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Maverex partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Science Based Targets initiative (SBTi)coreStrategic or Co-development PartnerMaverex has an SBTi-approved near-term science-based emissions reduction target. This partnership demonstrates Maverex's commitment to environmental sustainability and positions them as leaders in integrating environmental evidence in market access and policy strategy.

Scale indicators1 record

Recent moves5 records

Expansion highlights6 records

Maverex competitors and assessment

Company assessment

Emerging players

  • Maple Health Group: Smaller HEOR and market access consultancy serving pharma clients with evidence synthesis and HTA support — comparable niche positioning at an earlier scale stage.

Direct peers

  • Mtech Access: UK-based health economics and market access consultancy offering similar HEOR, HTA, and value communication services to pharma and MedTech clients. Most direct comparable by size, geography, and service mix.
  • Cogentia Healthcare Consulting: UK-headquartered market access and HEOR consultancy serving pharma and medical device companies with pricing, reimbursement, and HTA submission support — directly comparable niche competitor.
  • Envision Pharma Group: Global medical communications and HEOR/market access consultancy serving pharma clients across the product lifecycle. Comparable service portfolio with broader scale.
  • Valid Insight: Specialist market access and HEOR consultancy providing evidence synthesis, value communications, and HTA support to pharma and biotech — a similar niche player in the same service categories.
  • RTI Health Solutions: Specialized HEOR, market access, and real-world evidence consultancy within RTI International, serving pharma and MedTech with comparable deliverables (economic modelling, evidence synthesis, HTA support).

Broad incumbents

  • Evidera: Large HEOR and market access consultancy (part of Thermo Fisher's PPD) offering the full suite of services Maverex provides plus broader real-world evidence, epidemiology, and clinical outcomes — a much larger, established competitor.
  • IQVIA: Global leader in life sciences data, technology, and consulting, with a substantial HEOR and market access practice. Provides overlapping capabilities at significantly greater scale and geographic reach than Maverex.
  • Charles River Associates (Life Sciences Practice): Global consulting firm with a life sciences practice offering HEOR, pricing, and market access strategy. Overlaps with Maverex's strategic consulting offering but as part of a broader portfolio.

Others

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights7 records

Customer concentration

Maverex social profiles

Digital presence

Maverex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Maverex leadership team

Management profile

Number of profiles

Maverex funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Maverex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maverex

What does Maverex do?

Maverex is a HEOR and market access consultancy that provides strategic consulting services to global pharmaceutical, medical device, and diagnostic companies. Its core offering is an integrated suite of services spanning the product lifecycle — including global market access strategy, real world evidence, environmental sustainability assessments, health economic modelling, HTA submission support, value communications, and evidence synthesis. The firm is recognised as an industry leader in environmental sustainability assessments for healthcare products and care pathways.

Is Maverex a public or private company?

Maverex is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Maverex founded?

Maverex was founded in 2016. It employs 11 to 50 people.

Where is Maverex based?

Maverex is headquartered in Newcastle Upon Tyne, United Kingdom, in the Europe region.

How does Maverex make money?

One revenue line is on record: consulting Services.

Who are Maverex's main competitors?

Maple Health Group is listed as an emerging player. Direct peers are Mtech Access, Cogentia Healthcare Consulting, Envision Pharma Group, Valid Insight and RTI Health Solutions. Broad incumbents are Evidera, IQVIA and Charles River Associates (Life Sciences Practice). Health Economics Consulting (HEC) at Pharmaprojects / GlobalData is listed as an others.

Does Maverex have an API?

No public API is recorded for Maverex.

What industry is Maverex in?

Maverex's product category is Healthcare Market Access Consulting. Its primary akta.pro industry code is HLAIAKAB, Health Economics & Outcomes Research (HEOR), with a secondary code of HLAIAKAD, Payer & HTA Engagement (Reimbursement/Submissions). Its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales